Results 41 to 50 of about 64,512 (289)

p300/MDM2 Complexes Participate in MDM2-Mediated p53 Degradation [PDF]

Molecular Cell, 1998
Control of p53 turnover is critical to p53 function. E1A binding to p300/CBP translates into enhanced p53 stability, implying that these coactivator proteins normally operate in p53 turnover control. In this regard, the p300 C/H1 region serves as a specific in vivo binding site for both p53 and MDM2, a naturally occurring p53 destabilizer.
Grossman, Steven R, Perez, Marco, Kung, Andrew L, Joseph, Michael, Mansur, Claire, Xiao, Zhi-Xiong, Kumar, Sushant, Howley, Peter M, Livingston, David M   +8 more
openaire   +2 more sources

Dedifferentiated liposarcoma with heterologous spindle cell rhabdomyoblastic de-differentiation: An unusual pattern expanding the morphological spectrum

Indian Journal of Pathology and Microbiology, 2020
Dedifferentiated liposarcoma (DDLS) is characterized by a wide histopathological spectrum. Spindle cell type of rhabdomyoblastic dedifferentiation has been rarely described in case of DDLS.
Bharat Rekhi, Akshay D Baheti, Shraddha Patkar   +2 more
doaj   +1 more source

Independent regulation of P53 stabilisation and activation after Rb deletion in primary epithelial cells [PDF]

, 2010
We have previously reported that deletion of the retinoblastoma gene Rb leads to rapid but transient p53 stabilisation. We investigated here the pathways involved.
Bellamy, Christopher, Harrison, David J, Treanor, Louise, Prost, Sandrine, Harrison, David J., Harrison, David J.; id_orcid   +5 more
core   +1 more source

The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors [PDF]

International Journal of Molecular Sciences, 2019
Proteins that limit the activity of the tumour suppressor protein p53 are increasingly being targeted for inhibition in a variety of cancers. In addition to the development of small molecules, there has been interest in developing constrained (stapled) peptide inhibitors. A stapled peptide ALRN_6924 that activates p53 by preventing its interaction with
Srinivasaraghavan Kannan, Anthony W. Partridge, David P. Lane, Chandra S. Verma   +3 more
openaire   +4 more sources

Effect of the Ethanolic Extract of Eryngium billardieri on the Viability of the Triple-Negative Breast Cancer Cell Line (MDA-MB-231) and CDKN2A, MDM2, and HER2 Expression

European Journal of Biology
Objective: Currently, treating triple-negative breast cancer (TNBC) poses a significant challenge. Eryngium billardierei is widely employed as a medicinal plant, particularly for the treatment of cancers.
Azadeh Hekmat, Elaheh Ghanbari, Saeed Hesami Tackallou   +2 more
doaj   +1 more source

Reduced p53-MDM2 feedback promotes p53 and MDM2 expression.

, 2022
(A) Model simulations upon disruption of the MDM2-p53 feedback by weakening the feedback strength of MDM2 on p53 degradation to 50% (dashed green) or 20% (dashed yellow) of the original strength; simulations without disruption are shown as solid purple ...
Lukas S. Wijaya (8115686), Bob van de Water (108410), Huan Yang (36076), Muriel M. Heldring (13020365), Joost B. Beltman (9115841), Marije Niemeijer (1833334), Talel Lakhal (13020368), Sylvia E. Le Dévédec (10217235)   +7 more
core   +1 more source

The ubiquitin system in normal and infected germinal center B cells

FEBS Letters, EarlyView.
The ubiquitin system plays a central role in germinal center (GC) B cells, influencing differentiation to long‐lived memory B cells. Oncogenic gammaherpesviruses gain access to memory B cells by establishing latency in GC B cells. Mapping ubiquitin mechanisms in normal and infected GC B cells will define specific molecular circuits in B cells germane ...
Destiny Davis, Lesly Mejia, Emily K Moser   +2 more
wiley   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia. [PDF]

PLoS ONE, 2014
Nilotinib is a selective BCR-ABL tyrosine kinase inhibitor related to imatinib that is more potent than imatinib. Nilotinib is widely used to treat chronic myelogenous leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). The
Hailong Zhang, Lubing Gu, Tao Liu, Kuang-Yueh Chiang, Muxiang Zhou   +4 more
doaj   +1 more source

USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival

Molecular Oncology, EarlyView.
CLL cells rely on BCR‐mediated signalling for survival and proliferation in part through suppression of FOXO1. FOXO1 activity is regulated by a plethora of post‐translational modifications including phosphorylation and ubiquitination. We demonstrated that dual inhibition of BCR signalling and the deubiquitinase USP7 activates FOXO1, modulating its ...
Hassan N.B. Almuhanna, Jodie Hay, Michael W. Moles, Lucy Clarke, Jennifer Cassels, Alison Sefcick, Alison M. McCaig, Heather G. Jørgensen, Alison M. Michie   +8 more
wiley   +1 more source